AUM $5.2MER 0.47%NAV $34.64Holdings 73Inception Aug 2022
Price Chart
Key Statistics
Previous Close
$34.70Day Range
$34.74$35.24
52-Week Range
$21.78$36.08
Avg Volume
2.4KDividend Yield
1.00%Expense Ratio
0.47%AUM
$5.2MShares Outstanding
154.0KETF Grades
?ETF Grades compare this fund against others in the same category using percentile rankings across six factors. Grades range from A+ (top 5%) to F (bottom 20%). Updated daily.Sector Breakdown
| Sector | Weight % |
|---|---|
| Healthcare | 100.00% |
Country Allocation
| Country | Weight % |
|---|---|
| United States | 69.44% |
| Ireland | 5.76% |
| Canada | 4.47% |
| Netherlands | 4.13% |
| United Kingdom | 3.94% |
| Sweden | 2.14% |
| Denmark | 1.96% |
| South Korea | 1.86% |
| Switzerland | 1.18% |
| China | 1.17% |
| Australia | 1.11% |
| Japan | 0.88% |
| France | 0.69% |
| Israel | 0.51% |
| Other | 0.44% |
| Italy | 0.31% |
Fund Information
- Issuer
- iShares
- Category
- Healthcare
- Types
- GrowthTechnology
- Inception Date
- Aug 24, 2022
- Exchange
- NYSE_ARCA
- Description
- The iShares Neuroscience and Healthcare ETF seeks to track the investment results of an index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience.
Similar ETFs
The iShares Neuroscience and Healthcare ETF (IBRN) is an exchange-traded fund issued by iShares that launched on Aug 24, 2022. It currently manages $5.2M in assets under management. The fund charges an expense ratio of 0.47%. The fund holds 73 securities in its portfolio. It falls under the Healthcare category.
Top 10 holdings represent 44.7% of the fund
| Rank | Symbol | Name | Weight % | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | ALKS | ALKERMES | 5.58% | 6,446 | $290K |
| 2 | AXSM | AXSOME THERAPEUTICS INC | 5.56% | 1,138 | $289K |
| 3 | NBIX | NEUROCRINE BIOSCIENCES INC | 4.54% | 1,448 | $236K |
| 4 | ARGX | ARGENX SE ADR | 4.45% | 257 | $231K |
| 5 | XENE | XENON PHARMACEUTICALS INC | 4.44% | 4,419 | $231K |
| 6 | ARWR | ARROWHEAD PHARMACEUTICALS INC | 4.43% | 3,088 | $230K |
| 7 | PTCT | PTC THERAPEUTICS INC | 4.23% | 2,938 | $219K |
| 8 | CNTA | CENTESSA PHARMACEUTICALS AMERICAN | 3.97% | 5,186 | $206K |
| 9 | BIIB | BIOGEN INC | 3.87% | 1,004 | $201K |
| 10 | CPRX | CATALYST PHARMACEUTICALS INC | 3.66% | 6,048 | $190K |
| 11 | SRRK | SCHOLAR ROCK HOLDING CORP | 3.51% | 4,075 | $182K |
| 12 | ACAD | ACADIA PHARMACEUTICALS INC | 3.43% | 8,328 | $178K |
| 13 | DNLI | DENALI THERAPEUTICS INC | 3.16% | 7,800 | $164K |
| 14 | DNTH | DIANTHUS THERAPEUTICS INC | 2.94% | 1,998 | $153K |
| 15 | PRAX | PRAXIS PRECISION MEDICINES INC | 2.84% | 594 | $147K |
Page 1 of 2
Detailed Returns
| Period | Return | ETF |
|---|---|---|
| 1D | +0.56% | |
| 1W | +2.50% | |
| 1M | +0.12% | |
| 3M | +10.86% | |
| 6M | +8.93% | |
| YTD | +9.59% | |
| 1Y | +53.36% | |
| 3Y | +34.94% | |
| 5Y | +41.79% |
Moving Averages
20-Day MA
$34.67
Above 20-Day MA50-Day MA
$34.70
Above 50-Day MA200-Day MA
$31.11
Above 200-Day MAPrice with Moving Averages
Support & Resistance
52-Week High
$36.08
Current Price
$34.89
52-Week Low
$21.78
$21.78$36.08
Current Yield
1.00%
Annual Dividend
$0.4355
Frequency
1x/year
Last Ex-Date
Dec 16, 2025
Dividend History
| Ex-Date | Amount | Pay Date |
|---|---|---|
| Dec 16, 2025 | $0.3198 | Dec 19, 2025 |
| Dec 17, 2024 | $0.1011 | Dec 20, 2024 |
| Dec 20, 2023 | $0.0063 | Dec 27, 2023 |
| Jun 7, 2023 | $0.0082 | Jun 13, 2023 |
Dividend Payments Over Time
Category Comparison
| Metric | IBRN | Healthcare(176 ETFs) | Growth(409 ETFs) |
|---|---|---|---|
| Fund Info | |||
| Expense Ratio | 0.47% | 0.61% | 0.66% |
| AUM | $5.2M | $910.0M | $2.98B |
| Dividend Yield | 1.00% | 3.35% | 5.84% |
| Avg Volume | 2.4K | 275.1K | 224.0K |
| Holdings | 73 | 99 | 79 |
| Performance | |||
| 1-Month Return | -3.28% | +1.77% | +0.07% |
| 6-Month Return | +6.45% | +3.26% | +4.91% |
| YTD Return | +7.78% | +3.61% | +6.90% |
| 1-Year Return | +48.24% | +24.59% | +19.62% |
Compare with Another ETF
Search for an ETF to compare with IBRN:
FREE DOWNLOAD
The Beginner's Guide to ETFs
20 pages. Zero fluff. Everything you need to start investing in ETFs.
No spam. Unsubscribe anytime.